Peel Hunt LLP Form 8.5 (EPT/RI) - UDG Healthcare Plc (6312I)

TIDMUDG

RNS Number : 6312I

Peel Hunt LLP

13 August 2021

Ap24

FORM 38.5(a)

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 38.5(a) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS AND DEALING IN A CLIENT-SERVING CAPACITY

   1.       KEY INFORMATION 
 
Name of exempt principal    Peel Hunt LLP 
 trader 
Company dealt in            UDG Healthcare Plc 
                            ======================== 
Class of relevant security  EUR 05.5 Ordinary Shares 
 to which the dealings 
 being disclosed relate 
 (Note 1) 
                            ======================== 
Date of dealing             12 August 2021 
                            ======================== 
 
   2.        DEALINGS (Note 2) 
   (a)      Purchases and sales 
 
 Total number                 Highest price paid     Lowest price 
  of relevant                  (Note 3)               paid 
  securities acquired                                 (Note 3) 
 1,376                       1,079.25 GBP              1,078.25 GBP 
                       =========================  ================= 
 
 
 Total number           Highest price received     Lowest price 
  of securities          (Note 3)                   received 
  disposed                                          (Note 3) 
 1,376                  1,078.00 GBP                 1,078.00 GBP 
                 =============================  ================= 
 
   (b)      Derivatives transactions (other than options transactions) 
 
 Product     Nature of transaction   Number of relevant   Price per 
  name,       (Note 4)                securities           unit 
  e.g. CFD                            (Note 5)             (Note 3) 
                                     Nil 
            ======================  ===================  ========== 
 

Ap25

   (c)      Options transactions in respect of existing relevant securities 
   (i)       Writing, selling, purchasing or varying 
 
 Product      Writing,      Number of        Exercise   Type,            Expiry   Option 
  name,        selling,      securities       price      e.g. American,   date     money paid/received 
  e.g. call    purchasing,   to which                    European                  per unit 
  option       varying       the option                  etc.                      (Note 3) 
               etc.          relates (Note 
                             5) 
 
 
   (ii)      Exercising 
 
Product name,             Number of securities      Exercise price 
 e.g. call option                                    per unit (Note 
                                                     3) 
                    Nil 
                   ===========================  =================== 
 
   3.      OTHER INFORMATION 

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None

 
Date of disclosure            13 August 2021 
Contact name                  Paul Crispin 
                             =================== 
Telephone number              0207 418 8988 
                             =================== 
Name of offeree/offeror       UDG Healthcare Plc 
 with which connected 
                             =================== 
Nature of connection (Note    Broker to Offeree 
 6) 
                             =================== 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

FERUOSRRABUWAAR

(END) Dow Jones Newswires

August 13, 2021 07:00 ET (11:00 GMT)